11.67
3.73%
+0.42
KalVista Pharmaceuticals Inc stock is currently priced at $11.67, with a 24-hour trading volume of 233.73K.
It has seen a +3.73% increased in the last 24 hours and a +2.82% rose in the past month.
The chart indicates a potential bullish trend, as the stock is above the $11.20 pivot point. If it approaches the $11.62 resistance level, significant changes may occur.
Previous Close:
$11.25
Open:
$11.3
24h Volume:
233.73K
Market Cap:
$492.34M
Revenue:
-
Net Income/Loss:
$-108.30M
P/E Ratio:
-3.693
EPS:
-3.16
Net Cash Flow:
$-97.15M
1W Performance:
+3.27%
1M Performance:
+2.82%
6M Performance:
+38.27%
1Y Performance:
+19.69%
KalVista Pharmaceuticals Inc Stock (KALV) Company Profile
Name
KalVista Pharmaceuticals Inc
Sector
Industry
Phone
857-999-0075
Address
55 Cambridge Parkway, Suite 901 East, Cambridge, MA
KalVista Pharmaceuticals Inc Stock (KALV) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jun-15-20 | Initiated | H.C. Wainwright | Buy |
Jul-29-19 | Initiated | SVB Leerink | Outperform |
Mar-20-19 | Initiated | Needham | Buy |
Oct-30-18 | Initiated | Jefferies | Buy |
Sep-21-18 | Initiated | Cantor Fitzgerald | Overweight |
Aug-31-17 | Initiated | BTIG Research | Buy |
View All
KalVista Pharmaceuticals Inc Stock (KALV) Latest News
How To Trade (KALV) - Stock Traders Daily
Stock Traders Daily
KalVista Pharmaceuticals Announces New England Journal of Medicine Publishes Oral Sebetralstat Phase 3 Data ... - The Bakersfield Californian
The Bakersfield Californian
KalVista Pharmaceuticals Announces New England Journal of Medicine Publishes Oral Sebetralstat Phase 3 Data ... - Business Wire
Business Wire
KalVista Pharmaceuticals Announces New England Journal of Medicine Publishes Oral Sebetralstat Phase 3 Data ... - Chronicle-Tribune
Chronicle-Tribune
KalVista Pharmaceuticals Announces New England Journal of Medicine Publishes Oral Sebetralstat Phase 3 Data ... - Business Wire
Business Wire
KalVista Pharmaceuticals (NASDAQ:KALV) Stock Price Passes Below 50 Day Moving Average of $11.61 - MarketBeat
MarketBeat
KalVista Pharmaceuticals Inc Stock (KALV) Financials Data
KalVista Pharmaceuticals Inc (KALV) Net Income 2024
KALV net income (TTM) was -$108.30 million for the quarter ending January 31, 2024, a -19.38% decrease year-over-year.
KalVista Pharmaceuticals Inc (KALV) Cash Flow 2024
KALV recorded a free cash flow (TTM) of -$97.15 million for the quarter ending January 31, 2024, a -20.50% decrease year-over-year.
KalVista Pharmaceuticals Inc (KALV) Earnings per Share 2024
KALV earnings per share (TTM) was -$3.15 for the quarter ending January 31, 2024, a +11.76% growth year-over-year.
About KalVista Pharmaceuticals Inc
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, an intravitreally administered plasma kallikrein inhibitor that is in Phase II clinical trials for the treatment of DME; and KVD900, a potent inhibitor of plasma kallikrein, which is in Phase I clinical trial for treating HAE. The company is headquartered in Cambridge, Massachusetts.
Cap:
|
Volume (24h):